Search

everythinglearnresearchcommunity

for

Search:↓

Dr. Bloxham's 9-month update on FUT scar revision with Verteporfin shows promising results. Excitement is high for FUE, which appears highly effective based on Dr. Barghouthi's findings.

A compound called MTP3 from the Monoterpene family was found to be safe and highly effective at treating hair loss by inhibiting the FGF5 gene, but its identity is undisclosed for commercial reasons. No specific treatments like Minoxidil, finasteride, or RU58841 were discussed.

The conversation discusses hair regrowth results after using finasteride, minoxidil, and dermarolling for four months. Users inquire about dosages and when results were first noticed.

OP used finasteride, topical minoxidil, microneedling, and caffeine shampoo for hair loss. After 4 months, they saw progress with new, lighter-colored hairs.

A 23-year-old male has been experiencing hair loss since 2022 and has used minoxidil and dutasteride with reduced shedding but no hair regrowth. He is considering PRP with mesotherapy and red light therapy, GFC, or exosomes, with a preference for exosomes due to efficiency and a reputable clinic.

Federal funding cuts have delayed PP405 research, affecting hair loss treatment progress, though clinical trials will continue. The discussion highlights PP405's potential compared to minoxidil and finasteride and stresses the importance of government-funded research.

The user shared their 4-month progress using oral finasteride and topical minoxidil, with a specific application routine. They adjust the minoxidil application to manage costs, applying it daily with variations in quantity and additional tretinoin on certain days.

A 25-year-old who has been using minoxidil and finasteride for 4 years to treat hair loss, underwent a successful FUE hair transplant in Mumbai, India, in April 2023. The user reported positive results, including increased hair density and reduced frizziness, and plans to continue treatment for further growth.

A 33-year-old is experiencing positive hair regrowth after 4.5 months using 0.5mg finasteride, topical minoxidil, ketoconazole shampoo, and a 0.5mm derma stamp. They had initial shedding but now see less hair loss, with no sexual side effects and improved libido.

PP405 is likely fake, and JXL069 is an unrefined prototype with unknown side effects. It's advised to wait for the official PP405 release.

The conversation discusses GT20029 as a potential hair loss treatment that could act like a cure by targeting androgen receptors in scalp hair follicles. Specific treatments mentioned include GT20029, with a user expressing hope that it could make male pattern baldness obsolete.

GT20029, a new hair loss treatment, shows promising results but only a slight improvement over placebo. People are cautiously optimistic, discussing its potential and combining it with existing treatments like Minoxidil and Finasteride.

Follicopeptide (FOL005) by Coegin Pharma will launch as a cosmetic hair growth treatment by Q2 2025, showing similar efficacy to finasteride. Users discuss the benefits and skepticism of releasing hair loss treatments as cosmetics rather than drugs.

KX826 shows promise as a hair loss treatment with a 10% increase in hair count, but concerns about Kintor's marketing practices and the systemic effects of treatments like GT20029 and RU58841 remain. Users express skepticism and hope, with some preferring traditional treatments like finasteride and minoxidil.

The user shared a four-month update on their hair regrowth journey using 1mg daily finasteride, 5mg daily oral minoxidil, and weekly dermarolling, noting significant improvement in hair thickness and uniform growth. They reported no side effects from minoxidil except increased hair growth on arms, fingers, and eyelashes.

The user has been using 0.5mg finasteride daily for 4 years and is considering adding minoxidil, either oral or topical, to improve hairline density. They are also contemplating a hair transplant and have been using derma rolling and ketoconazole inconsistently.

Maneup GHK-Cu peptide was used for hair loss, resulting in some hair growth in the receded hairline, but the new hairs were dry and split easily. Users discussed their experiences with this treatment.

The conversation discusses a video about GT20029, a treatment for hair loss, and its comparison to KX826. Users express interest in the video's effectiveness and potential, and praise its informative content.

The user had two FUT hair transplants with 4,600 grafts for increased density, costing about $11,000 each, and has been using oral minoxidil and finasteride for over five years without side effects. The results are natural-looking with no visible scarring, and the user finds the procedure valuable despite the cost.

User tried oral finasteride, topical finasteride, topical dutasteride, and RU58841 but experienced side effects. They discuss upcoming treatments like clascoterone, pyrilutamide, gt20029, and KY19382 as potential options.

Pelage Pharmaceuticals' PP405 aims to treat hair loss by reactivating dormant hair follicle stem cells, showing promising results in early trials. The company plans to present their findings at the American Academy of Dermatology Annual Meeting in 2026.

A user shared progress pictures after 4 months of using 1mg finasteride, a 0.25mm derma roller with rosemary oil, and biotin pills for hair loss. They reported being very happy with the results.

The user shared their 4-month progress using a topical solution of 5% minoxidil and 0.1% finasteride, reporting initial shedding that stopped after 2.5 months and noticeable regrowth, especially in the crown area. They use Glenmark Hair4U F from India and have experienced no side effects.

New treatments for AGA are emerging, including pyrilutumide, gt0029, scube3, kx-826, and pp405. Verteporfin is mentioned as a promising option.

PP405 is a potential hair loss treatment that may work by blocking signals that cause hair cells to stop growing, requiring daily application for effectiveness. It could serve as an alternative to minoxidil and finasteride, but it is not yet available on the market and may take several years to be released.

A 44-year-old user experienced hair regrowth using a topical spray combining 0.3% finasteride and 7% minoxidil after switching from oral finasteride due to side effects. The user reported noticeable improvements in hair thickness after four months without any side effects from the topical treatment.

TDM-105795 is a potential hair growth stimulant that works differently from minoxidil and could be used alongside it for enhanced growth. It completed phase 2 trials in 2024, with a medium to high chance of release in 2026, but lacks recent updates or phase 3 trial information.

A 42-year-old user shared a 4-month update on their hair regrowth using a "nuclear stack" including oral and topical minoxidil, dutasteride, RU58841, micro-needling, keto shampoo, saw palmetto, biotin, multivitamins, scalp massages, and inversion table. They reported significant progress with minimal side effects and plan to continue the routine.

User shares 4-month hairline progress using minoxidil, finasteride, nizoral, and dermarolling. Others discuss treatment details and express admiration for the results.

The conversation discusses the potential of a new hair loss treatment, GT20029, which targets androgen receptors in the scalp and is in phase 1 trials in China. Users express hope that this treatment will be more effective than current options like Minoxidil and Finasteride.